Literature DB >> 15504829

Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.

Klaudia Kosowska1, Kim Credito, Glenn A Pankuch, Dianne Hoellman, Gengrong Lin, Catherine Clark, Bonifacio Dewasse, Pamela McGhee, Michael R Jacobs, Peter C Appelbaum.   

Abstract

The MIC at which 50% of strains are inhibited (MIC(50)) and the MIC(90) of GW 773546, a novel macrolide, were 1.0 and 2.0 microg/ml, respectively, for 223 beta-lactamase-positive, beta-lactamase-negative, and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains. The MIC(50)s and MIC(90)s of GW 708408, a second novel macrolide, and telithromycin, an established ketolide, were 2.0 and 4.0 microg/ml, respectively, while the MIC(50) and MIC(90) of azithromycin were 1.0 and 2.0 microg/ml, respectively. The MIC(50) and MIC(90) of erythromycin were 4.0 and 8.0 microg/ml, respectively; and those of clarithromycin were 4.0 and 16.0 microg/ml, respectively. All compounds except telithromycin were bactericidal (99.9% killing) against nine strains at two times the MIC after 24 h. Telithromycin was bactericidal against eight of the nine strains. In addition, both novel macrolides and telithromycin at two times the MIC showed 99% killing of all nine strains after 12 h and 90% killing of all strains after 6 h. After 24 h, all drugs were bactericidal against four to seven strains when they were tested at the MIC. Ten of 11 strains tested by multistep selection analysis yielded resistant clones after 14 to 43 passages with erythromycin. Azithromycin gave resistant clones of all strains after 20 to 50 passages, and clarithromycin gave resistant clones of 9 of 11 strains after 14 to 41 passages. By comparison, GW 708408 gave resistant clones of 9 of 11 strains after 14 to 44 passages, and GW 773546 gave resistant clones of 10 of 11 strains after 14 to 45 passages. Telithromycin gave resistant clones of 7 of 11 strains after 18 to 45 passages. Mutations mostly in the L22 and L4 ribosomal proteins and 23S rRNA were detected in resistant strains selected with all compounds, with alterations in the L22 protein predominating. Single-step resistance selection studies at the MIC yielded spontaneous resistant mutants at frequencies of 1.5 x 10(-9) to 2.2 x 10(-6) with GW 773546, 1.5 x 10(-9) to 6.0 x 10(-4) with GW 708408, and 7.1 x 10(-9) to 3.8 x 10(-4) with telithromycin, whereas the frequencies were 1.3 x 10(-9) to 6.0 x 10(-4) with erythromycin and azithromycin and 2.0 x 10(-9) to 2.0 x 10(-3) with clarithromycin. Alterations in the L22 protein (which were predominant) and the L4 protein were present in mutants selected by the single-step selection process. The postantibiotic effects of GW 773546, GW 708408, and telithromycin for seven H. influenzae strains were 6.6 h (range, 5.2 to 8.8 h), 4.7 h (range, 2.6 to 6.9 h), and 6.4 h (range, 3.8 to 9.7 h), respectively. The results of in vitro studies obtained with both novel macrolides were similar to those obtained with telithromycin and better than those obtained with older macrolides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504829      PMCID: PMC525432          DOI: 10.1128/AAC.48.11.4113-4119.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Susceptibility testing of Haemophilus influenzae--an international collaborative study in quality assessment.

Authors:  S F Yeo; E Akalin; S Arikan; R Auckenthaler; T Bergan; K Dornbusch; A J Howard; W Hryniewicz; R N Jones; G Koupari; N J Legakis; J McLaughlin; C Ozkuyumcu; A Percival; I Phillips; D Reeves; R Spencer; R E Warren; J D Williams
Journal:  J Antimicrob Chemother       Date:  1996-09       Impact factor: 5.790

2.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.

Authors:  M L Zeckel; K D Jacobson; F J Guerra; D G Therasse; D Farlow
Journal:  Clin Ther       Date:  1992 Mar-Apr       Impact factor: 3.393

4.  Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.

Authors:  F W Goldstein; M F Emirian; A Coutrot; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes.

Authors:  J P Maskell; A M Sefton; J D Williams
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.

Authors:  R Dagan; E Leibovitz; D M Fliss; A Leiberman; M R Jacobs; W Craig; P Yagupsky
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.

Authors:  Mihaela Peric; Bülent Bozdogan; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-09-30       Impact factor: 5.790

9.  Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.

Authors:  G A Pankuch; D B Hoellman; G Lin; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

View more
  7 in total

1.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

4.  Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics.

Authors:  Maxim S Svetlov; Nora Vázquez-Laslop; Alexander S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

Review 5.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.

Authors:  Tatiana Bogdanovich; Bülent Bozdogan; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.